bluebird bio Inc (NAS:BLUE)
$ 0.4171 0.0121 (2.99%) Market Cap: 81.10 Mil Enterprise Value: 376.50 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 31/100

bluebird bio Inc at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top Transcript

Jan 09, 2020 / 07:00PM GMT
Release Date Price: $58.9 (-0.86%)
Salveen Jaswal Richter
Goldman Sachs Group Inc., Research Division - VP

Good afternoon, everyone. Thanks for joining us. I'm Salveen Richter, I cover the biotechnology sector on Goldman Sachs, and we're very pleased to have the CEO or Chief

(technical difficulty)

of bluebird with us, Nick Leschly.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group Inc., Research Division - VP

So Nick, you have with us the evolution of bluebird over the last decade, and the company is a pioneer in the field of genomic medicine. So how does the company and industry today compare to your 10-year view from when you first started as CEO?

Nick Leschly
bluebird bio, Inc. - President, CEO & Director

Well, first, thanks, Salveen, for having me here. I appreciate it. And you're always good about asking questions that I'm not prepared to answer. So 10 years, long time. I tend to measure that. And now my kids are leaving me, going to college and things like that. So it's been a big run in that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot